OxPL

Aortic Valve Disease Is Not a Monogenetic Disorder

“…Although the randomized studies in the field of statin therapy in CAVD have been negative, there is 1 open label study entitled RAAVE (Rosuvastatin Affecting Aortic Valve Endothelium) wherein the patients who received rosuvastatin according to the Adult Treatment Panel guidelines for lowering low-density lipoprotein did slow progression of disease after 16 months (4) . In the future, studies evaluating LPA, autotaxin, Lrp5, low-density lipoprotein receptor, oxidized phospholipids (5) , which activate the osteogenic cascade in the aortic valve, will be critical for the future development of randomized clinical trials.…”